含苯扎氯铵的沙丁胺醇持续雾化与儿童重症哮喘住院结局
该回顾性队列研究比较了<18岁急性哮喘发作住院患儿接受含与不含苯扎氯铵(BAC)的沙丁胺醇持续雾化治疗的临床结局。共纳入477例(BAC组236例,对照组241例)。BAC组持续雾化时间显著更长(中位9 vs 6小时),24小时仍需持续雾化比例更高(15.7% vs 5.8%),对照组停止持续雾化及额外呼吸支持的可能性更高。结论提示BAC为沙丁胺醇功能性拮抗剂,无防腐剂沙丁胺醇制剂用于持续雾化可能更安全。
要点
- 含BAC的沙丁胺醇持续雾化与更长的雾化时间和更多额外呼吸支持相关。
- 24小时时BAC组15.7%仍需持续雾化,对照组仅5.8%。
- 对照组停止持续雾化的可能性高79%(HR 1.79),停止额外呼吸支持高43%(HR 1.43)。
核心结论
- BAC是沙丁胺醇的功能性拮抗剂,与更长的持续雾化治疗时间和额外呼吸支持相关,提示无防腐剂沙丁胺醇制剂用于持续雾化更安全。
研究设计与样本
- 回顾性队列研究,比较<18岁接受含BAC与不含BAC的沙丁胺醇持续雾化的急性哮喘发作住院患儿,共纳入477例(BAC组236例,对照组241例)。
主要发现
- BAC组持续雾化时间中位9小时,对照组中位6小时。
- 24小时时BAC组15.7%仍需持续雾化,对照组为5.8%。
- 对照组在任何时间点停止持续雾化的可能性高79%(HR 1.79;95%CI 1.45–2.22;P<.001)。
- 对照组停止额外呼吸支持的可能性高43%(HR 1.43;95%CI 1.16–1.75;P<.001)。
临床怎么用
- 儿科临床对重症哮喘需持续雾化沙丁胺醇的住院患儿,可优先考虑无防腐剂(不含BAC)的沙丁胺醇制剂。
局限性
- 研究为回顾性队列设计,可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The albuterol dropper bottle used to prepare solutions for continuous nebulization contains the preservative benzalkonium chloride (BAC). BAC, by itself, has been shown to cause bronchospasm. We hypothesized that BAC would decrease the therapeutic efficacy of albuterol in patients with acute asthma exacerbations. METHODS: We performed a retrospective cohort study comparing the clinical outcomes of patients <18 years of age receiving continuous nebulized albuterol with and without BAC. For the primary end point (duration of continuous albuterol nebulization), we compared the 2 groups with Kaplan-Meier estimate of survival curves, conducted a log-rank test of difference, and adjusted for baseline characteristics using multivariable Cox regression. A P value <.05 was considered significant. RESULTS: A total of 477 patients were included in the analysis (236 exposed to BAC and 241 controls). The duration of continuous nebulization was significantly longer in the BAC group than in the control group (median of 9 vs 6 hours; 15.7% required continuous nebulization compared to 5.8% of controls at 24 hours). The control group was 79% more likely to stop continuous nebulization at any particular point in time (hazard ratio 1.79; 95% confidence interval: 1.45 to 2.22; P < .001) and 43% more likely to stop additional respiratory support (hazard ratio 1.43; 95% confidence interval: 1.16 to 1.75; P < .001). CONCLUSIONS: BAC is a functional albuterol antagonist associated with a longer duration of continuous albuterol nebulization treatment and additional respiratory support, suggesting that preservative-free albuterol formulations are safer for use in continuous nebulization.
引用
- Pertzborn MC, Prabhakaran S, Abu-Hasan M, et al. Continuous Albuterol With Benzalkonium in Children Hospitalized With Severe Asthma. Pediatrics. 2020. PMID: 32165556. doi:10.1542/peds.2019-0107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。